Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis.

Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE.

Cancer Discov. 2019 Dec 3. pii: CD-19-0672. doi: 10.1158/2159-8290.CD-19-0672. [Epub ahead of print]

PMID:
31796433
2.

The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.

Erkes DA, Field CO, Capparelli C, Tiago M, Purwin TJ, Chervoneva I, Berger AC, Hartsough EJ, Villanueva J, Aplin AE.

Pigment Cell Melanoma Res. 2019 Sep;32(5):687-696. doi: 10.1111/pcmr.12788. Epub 2019 May 20.

PMID:
31063649
3.

CADM1 is a TWIST1-regulated suppressor of invasion and survival.

Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH 3rd, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE.

Cell Death Dis. 2019 Mar 25;10(4):281. doi: 10.1038/s41419-019-1515-3.

4.

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Vido MJ, Le K, Hartsough EJ, Aplin AE.

Cell Rep. 2018 Nov 6;25(6):1501-1510.e3. doi: 10.1016/j.celrep.2018.10.049.

5.

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.

Hartsough EJ, Kugel CH 3rd, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE.

Mol Cancer Ther. 2018 Jan;17(1):84-95. doi: 10.1158/1535-7163.MCT-17-0705. Epub 2017 Nov 13.

6.

αC IN, αC OUT-that's what it's all about.

Hartsough EJ, Vido MJ.

Pigment Cell Melanoma Res. 2017 Mar;30(2):177-178. doi: 10.1111/pcmr.12549. Epub 2016 Nov 30. No abstract available.

PMID:
27801548
7.

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.

Hartsough EJ, Aplin AE.

Clin Cancer Res. 2016 Apr 1;22(7):1550-2. doi: 10.1158/1078-0432.CCR-15-3054. Epub 2016 Feb 3.

8.

Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.

Kugel CH 3rd, Hartsough EJ, Davies MA, Setiady YY, Aplin AE.

Cancer Res. 2014 Aug 1;74(15):4122-32. doi: 10.1158/0008-5472.CAN-14-0464. Epub 2014 Jul 17.

9.

Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

Hartsough EJ, Basile KJ, Aplin AE.

Mol Cancer Res. 2014 May;12(5):795-802. doi: 10.1158/1541-7786.MCR-13-0581. Epub 2014 Feb 11.

10.

Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.

Basile KJ, Le K, Hartsough EJ, Aplin AE.

Pigment Cell Melanoma Res. 2014 May;27(3):479-84. doi: 10.1111/pcmr.12218. Epub 2014 Feb 10.

11.

Lysine methylation promotes VEGFR-2 activation and angiogenesis.

Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, Marquez VE, Zhdanova IV, Weinberg J, Costello CE, Rahimi N.

Sci Signal. 2013 Dec 3;6(304):ra104. doi: 10.1126/scisignal.2004289.

12.

In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors.

Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE.

Cancer Res. 2013 Dec 1;73(23):7101-10. doi: 10.1158/0008-5472.CAN-13-1628. Epub 2013 Oct 11.

13.

A STATement on vemurafenib-resistant melanoma.

Hartsough EJ, Aplin AE.

J Invest Dermatol. 2013 Aug;133(8):1928-9. doi: 10.1038/jid.2013.136.

Supplemental Content

Loading ...
Support Center